🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Satya Das

Therapeutics Clinical Research

ORCID: 0000-0002-7625-1039
Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab”.

Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab

Clinical Colorectal Cancer(2020)10.1016/j.clcc.2020.02.006
N/A
1.7DataRank · unranked
25 citations

Audrey Allen, Jordan Berlin, Satya Das

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer

The Oncologist(2025)10.1093/oncolo/oyaf400
N/A
0.104DataRank · unranked
1 citations

Shannon Stockton, Heloisa P. Soares, Farshid Dayyani, Anwaar Saeed, Edward Kim +12 more

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

The Oncologist(2021)10.1002/onco.13741
N/A
0DataRank · unranked
48 citations

Subir Goyal, Yoanna S Pumpalova, Mohamad Bassam Sonbol, Satya Das, Sigurdís Haraldsdóttir +10 more

First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Journal of Nuclear Medicine(2021)10.2967/jnumed.120.261594
N/A
0DataRank · unranked
30 citations

Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman +9 more

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.363
N/A
0DataRank · unranked
1 citations

Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah +9 more

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4109
N/A
0DataRank · unranked
0 citations

Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad +13 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179
N/A
0DataRank · unranked
5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096
N/A
0DataRank · unranked
9 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more

Validating enhancer signature classifications (ESCs) in pancreatic neuroendocrine tumors (PNETs).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.627
N/A
0DataRank · unranked
0 citations

Chanjuan Shi, Jordan Berlin, Satya Das, Vincent Quoc‐Huy Trinh